#AS­CO21: Gilead­'s Trodelvy reads out new sub­group da­ta show­ing ben­e­fit in ear­li­er-line TNBC pa­tients

With As­traZeneca and Dai­ichi sniff­ing at its trail, Gilead has worked hard to hold an ad­van­tage for ADC Trodelvy in par­tic­u­lar­ly hard-to-treat breast can­cer pa­tients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER